

# P8106 Midterm - Report

Kate Colvin (KAC2301), Jeong Yun (Lizy) Choi (JC6452), and Flora Pang (FP2513)

## Introduction

In this project, our team investigated antibody responses to a newly authorized vaccine. The primary outcome of interest is patient log-transformed antibody level measured via dried blood spots. This dataset includes a range of demographic and clinical predictors, such as age, gender, race/ethnicity, smoking status, BMI, chronic conditions, and time since vaccination.

Our goal is to develop a predictive model that characterizes how these factors influence antibody responses and assess how well this model generalizes to a new independent dataset collected at a later time point. By doing so, we hope to identify key predictors of antibody response and evaluate the generalizability of our model across different dataset.

## Exploratory Analysis

Our full combined dataset includes 6,000 patients and contains demographic and health information, time since the patient received the vaccine, and log-transformed antibody level. There are two different subsets of data: data on 5,000 patients was initially collected for model training, and data on 1,000 additional patients was independently collected several months later for model testing and evaluation.

Patients in both datasets have similar demographic and health characteristics (Table 1), but patients from the second collected dataset have a greater time since receiving the vaccine (an additional few months), and therefore slightly lower observed log-transformed antibody levels (Figures 1 and 2). Because we are more likely to observe lower antibody levels from patients in the testing dataset, it's possible that this difference may impact the prediction performance of our models, which are trained using the initial dataset. After plotting the most correlated quantitative variables versus log-transformed antibody level, we can see that the fitted line for the testing data is always flatter than the line of the training data, indicating a weaker relationship between these variables and the response (Figures 7-9).

Across gender and smoking status, there were very slight differences in the observed antibody levels. Women had slightly greater antibody responses than men overall (Figure 3 and Table 2), while current smokers had slightly lower antibody responses than former and never-smokers (Figure 5 and Table 4). There were no observed differences in antibody responses across race (Figure 4 and Table 3). The quantitative variables that were most correlated with log-transformed antibody level were BMI, weight, and age. It's important to note that several predictors are also correlated with each other, such as BMI and weight, BMI and height, and SBP and age (Figure 6), which will impact variable selection.

## Model Training

In this analysis, we trained three different models: Multiple Linear Regression (MLR), LASSO Regression, and Multivariate Adaptive Regression Splines (MARS). The following sections provides each step in the model training process, from pre-processing to final model selection.

## Multiple Linear Regression (MLR) Model

We started by fitting a MLR model with all available predictors in the dataset using ordinary least squares regression (OLS).

The model was trained using the `lm()` function and the training process involved fitting the model to the data, estimating the regression coefficients for each predictor, and computing the residuals. The code below was used:

```
mlr_model <- lm(log_antibody ~ ., data = dat1)
```

The coefficients were estimated through OLS regression, and the residuals were checked for normality. The model was trained on the entire training dataset, and no regularization was applied. (Table 5)

## LASSO Model

To address potential multi-collinearity and perform feature selection, we used LASSO Regression, applying L1 regularization to shrink the coefficients of less important features to zero. The LASSO model was trained using the `glmnet` package.

Since LASSO is sensitive to differences in scale among predictor variables, numerical predictors were standardized before training to ensure fair comparison across variables. The `preProcess()` function from the `caret` package was used. The same transformations were applied to the validation and test datasets to maintain consistency.

The training procedure involved:

1. Creating a matrix of predictor variables (x) and a vector of the response variable (y)
2. Using cross-validation to select the best lambda (regularization parameter) based on the model's performance. The model with the lowest cross-validation error was used for evaluation.

```
lasso_model <- cv.glmnet(x_train, y_train, alpha = 1)
best_lambda <- lasso_model$lambda.min
lasso_final <- glmnet(x_train, y_train, alpha = 1, lambda = best_lambda)
```

## Multivariate Adaptive Regression Splines (MARS) Model

Non-linear regression MARS model automatically selects the best interactions and non-linear transformations of predictors. We first trained the MARS model without tuning, then used cross-validation to finetune it and determine the optimal number of terms and the degree of interactions (Table 6).

```
mars_model <- earth(log_antibody ~ ., data = dat1)
mars_tune <- train(log_antibody ~ ., data = dat1, method = "earth",
                  trControl = train_control, tuneGrid = tune_grid)
mars_model_tune <- train(log_antibody ~ .,
                        data = dat1,
                        method = "earth",
                        trControl = train_control,
                        tuneGrid = data.frame(nprune = 10, degree = 1))
```

The best parameters were selected as follows:

- $\text{nprune} = 10$ : The final model had 10 terms (lowest Generalized Cross Validation score)
- $\text{degree} = 1$ : The degree of interaction was set to 1, which considers only pairwise interactions between features.

## Model Evaluation and Results

To evaluate predictors of log antibody response, we trained three models using the original dataset (dat1): Multiple Linear Regression (MLR), LASSO Regression, and Multivariate Adaptive Regression Splines (MARS). Each model was then tested on an independent dataset (dat2) to assess generalizability. Model performance was evaluated using Root Mean Squared Error (RMSE), which captures prediction accuracy, and Adjusted R-squared (Adj.  $R^2$ ), which measures the proportion of variability explained while accounting for model complexity.

Among the three models, MARS model (Table 6) showed the best overall performance, with the lowest RMSE (0.533) and the highest adjusted  $R^2$  (0.169). Both MLR and LASSO had identical RMSE values (0.568), but MLR explained more variance (Adj.  $R^2 = 0.149$ ) than LASSO (Adj.  $R^2 = 0.110$ ), suggesting that LASSO may have underfit slightly by shrinking less informative predictors. These results are summarized in Table 7.

MARS was particularly well-suited for this dataset because of its ability to flexibly model non-linear relationships and interactions, which are common in immune response data. Variables like BMI are unlikely to relate to antibody levels in a strictly linear way (Figure 6). While linear models assume constant change across the predictor range, MARS allows for thresholds and curve shapes that better reflect biological processes. This likely contributed to its stronger performance on the test set.

We also compared model performance by resampling each model through the caret package and compared RMSE distributions across models (Figure 10). MARS had the lowest median RMSE, reinforcing its predictive strength, though its variability across folds was slightly wider than MLR. MARS model captured threshold effects and non-linear trends (e.g., antibody response plateauing with age or BMI), which linear models cannot.

The variables chosen by the final MARS model were age, gender, BMI, smoking status, and time since vaccination. Being a man and a current smoker were found to have the biggest impacts on antibody response. Specifically, being a man was associated with a lower antibody response compared to being a woman ( $\text{beta} = -0.2963$ ) and being a current smoker was associated with a lower antibody response compared to being a former or never-smoker ( $\text{beta} = -0.2051$ ).

In summary, MARS was selected as the final model due to its ability to handle complex, non-linear patterns in the data and its strong performance on an independent dataset. While it exhibited slightly more variability in resampling, it offered the best balance of accuracy and flexibility. These findings highlight the importance of model selection based on data structure and analysis goals — and support the use of flexible modeling strategies in understanding antibody responses to vaccination.

For the patients in this study, BMI, gender, age, smoking status, and time since receiving the vaccine were the most important predictors of antibody response. The impact of demographic and clinical factors on antibody responses to vaccines is an important area that warrants further study; this research can be used by patients, doctors, and public health officials to inform clinical decision-making and health policy.

Table 1: Summary of Patient Testing and Training Data (N=6000)

Characteristic	Overall N = 6,000 <sup>1</sup>	Testing Data N = 1,000 <sup>1</sup>	Training Data N = 5,000 <sup>1</sup>	p-value <sup>2</sup>
Age	60.0 (57.0, 63.0)	60.0 (57.0, 63.0)	60.0 (57.0, 63.0)	0.9
Gender				0.7
Female	3,082 (51%)	509 (51%)	2,573 (51%)	
Male	2,918 (49%)	491 (49%)	2,427 (49%)	
Race				0.6
Asian	333 (5.6%)	55 (5.5%)	278 (5.6%)	
Black	1,235 (21%)	199 (20%)	1,036 (21%)	
Hispanic	548 (9.1%)	83 (8.3%)	465 (9.3%)	
White	3,884 (65%)	663 (66%)	3,221 (64%)	
Smoking				0.8
Current	589 (9.8%)	103 (10%)	486 (9.7%)	
Former	1,800 (30%)	296 (30%)	1,504 (30%)	
Never	3,611 (60%)	601 (60%)	3,010 (60%)	
Height (cm)	170.1 (166.1, 174.2)	170.2 (166.1, 174.2)	170.1 (166.1, 174.3)	0.7
Weight (kg)	80 (75, 85)	80 (75, 84)	80 (75, 85)	0.8
BMI	27.60 (25.80, 29.50)	27.60 (25.80, 29.60)	27.60 (25.80, 29.50)	0.9
Diabetes	929 (15%)	157 (16%)	772 (15%)	0.8
Hypertension	2,754 (46%)	456 (46%)	2,298 (46%)	0.8
Systolic Blood Pressure (mmHg)	130 (124, 135)	130 (124, 135)	130 (124, 135)	0.3
LDL Cholesterol (mg/dL)	110 (96, 124)	112 (96, 124)	110 (96, 124)	0.4
Time Since Vaccinated (days)	116 (82, 152)	171 (140, 205)	106 (76, 138)	<0.001
Log-Transformed Antibody Level	10.06 (9.65, 10.45)	9.93 (9.50, 10.32)	10.09 (9.68, 10.48)	<0.001

<sup>1</sup>Median (Q1, Q3); n (%)

<sup>2</sup>Wilcoxon rank sum test; Pearson's Chi-squared test

Figure 1: Distribution of Log-Transformed Antibody Level, by Data Set




Figure 2: Distribution of Days Since Vaccination, by Data Set




Figure 3: Distribution of Log-Transformed Antibody Level, by Gender




Figure 4: Distribution of Log-Transformed Antibody Level, by Race




Figure 5: Distribution of Log-Transformed Antibody Level, by Smoking




Table 2: Log-Transformed Antibody Level, by Gender

Characteristic	Female N = 3,082 <sup>1</sup>	Male N = 2,918 <sup>1</sup>	p-value <sup>2</sup>
log_antibody	10.20 (9.79, 10.58)	9.93 (9.51, 10.30)	<0.001

<sup>1</sup>Median (Q1, Q3)<sup>2</sup>Wilcoxon rank sum test

Table 3: Log-Transformed Antibody Level, by Race

Characteristic	Asian N = 333 <sup>1</sup>	Black N = 1,235 <sup>1</sup>	Hispanic N = 548 <sup>1</sup>	White N = 3,884 <sup>1</sup>	p-value <sup>2</sup>
log_antibody	10.06 (9.62, 10.44)	10.08 (9.65, 10.44)	10.03 (9.61, 10.42)	10.06 (9.65, 10.46)	0.4

<sup>1</sup>Median (Q1, Q3)<sup>2</sup>Kruskal-Wallis rank sum test

Table 4: Log-Transformed Antibody Level, by Smoking Status

Characteristic	Current N = 589 <sup>1</sup>	Former N = 1,800 <sup>1</sup>	Never N = 3,611 <sup>1</sup>	p-value <sup>2</sup>
log_antibody	9.91 (9.46, 10.28)	10.10 (9.66, 10.48)	10.07 (9.68, 10.46)	<0.001

<sup>1</sup>Median (Q1, Q3)<sup>2</sup>Kruskal-Wallis rank sum test

Figure 6: Correlation Matrix of Numerical Variables




Figure 7: Log-Transformed Antibody Level vs. BMI




Figure 8: Log-Transformed Antibody Level vs. Weight






Figure 9: Log-Transformed Antibody Level vs. Age




Table 5: Regression Coefficients for MLR Model

Term	Estimate
(Intercept)	26.6752
age	-0.0206
gender	-0.2975
race2	-0.0060
race3	-0.0075
race4	-0.0418
smoking1	0.0220
smoking2	-0.1935
height	-0.0821
weight	0.0859
bmi	-0.2978
diabetes	0.0113
hypertension	-0.0179
sbp	0.0015
ldl	-0.0002
time	-0.0003

Table 6: Regression Coefficients for MARS Model

Term	Estimate
(Intercept)	10.8474
h(27.8-bmi)	-0.0620
h(time-57)	-0.0023
h(57-time)	-0.0335
gender	-0.2963
h(age-59)	-0.0230
h(59-age)	0.0161
smoking2	-0.2051
h(bmi-23.7)	-0.0844

Figure 10: Model Performance Comparison: RMSE Across Resamples




Table 7: Model Performance on Independent Test Set (dat2)

Model	RMSE	Adjusted R-squared	Notes
Multiple Linear Regression (MLR)	0.568	0.149	Baseline model; assumes linear relationships
LASSO Regression	0.568	0.110	Performs variable selection via L1 regularization
MARS	0.533	0.169	Best performance; captures non-linear effects